Biotech VC Funds

Wellington Management is a global investment management firm that has expanded its private investing capabilities with a dedicated platform focusing on various sectors and stages of the private markets. This includes early-stage venture capital through to late-stage growth investments. With over $8 billion raised for private investments, the firm leverages its extensive network of over 1,000 investment professionals to provide comprehensive support to its portfolio companies. Wellington's venture capital arm, Wellington Access Ventures (WAV), recently closed its first early-stage fund, Wellington Venture Investments I, with $150 million in commitments. This fund focuses on investing in sectors such as artificial intelligence, DevOps, fintech, digital health, and consumer technology. The WAV team is dedicated to supporting diverse founder-led companies, recognizing the value in partnering with historically overlooked entrepreneurs to drive long-term growth and meaningful change. Key members of the WAV team include Jackson Cummings, Frederik Groce, Sasha McKenzie, and Van Jones. They emphasize closing the access and resource gaps in venture capital, aiming to create a more equitable future by investing in dynamic and ambitious founders from diverse backgrounds. Wellington Management's private investing platform combines deep private market expertise with the firm's broader public market knowledge, providing a robust support system for both investors and entrepreneurs.

Wellington Partners is a Munich-based venture capital firm, focusing on early- and growth-stage investments in life sciences. Established in 1998, the firm has been instrumental in backing innovative companies in biotechnology, medical devices, digital health, and diagnostics across Europe. With over €1.2 billion under management, including €590 million dedicated specifically to life sciences, Wellington Partners has a robust track record of supporting breakthrough technologies aimed at improving healthcare. Their portfolio includes successful companies like Carisma Therapeutics, Onward Medical, and Symetis, many of which have achieved successful IPOs or acquisitions. Wellington's investment strategy goes beyond capital infusion, offering extensive operational support and access to their global network to help startups navigate regulatory approvals, clinical development, and market expansion. The firm typically invests in the range of €0.5 million to €20 million per company and plays a hands-on role in scaling businesses globally, with a strong presence in key markets like Europe and the U.S. Through their dedicated team of MDs and PhDs, Wellington Partners continues to drive transformative healthcare innovations.

Westbound Equity Partners, formerly Concrete Rose Capital, is a venture capital firm headquartered in Menlo Park, California, committed to investing in startups led by underrepresented founders or building solutions focused on diverse communities. Launched initially in 2019, Westbound has grown its impact through its latest $100 million fund, which targets early-stage ventures with a mission to foster generational wealth and diversity in tech. Founders Sean Mendy and Ian Beadle, both seasoned investors, drive the firm’s approach, emphasizing cultural inclusivity and providing robust support through an extensive professional network that includes industry leaders like Andre Iguodala and Jeff Weiner. Westbound’s investment strategy emphasizes financial and social capital, with funds directed to companies demonstrating potential for both high impact and inclusivity, like Esusu and PlanetFWD. Each investment is bolstered by Westbound’s Talent Network, connecting founders with diverse talent pools and advising on company culture to enhance equitable team practices and inclusive product development. This social and financial support framework is designed to break cycles of underrepresentation in venture capital while achieving substantial returns. In addition to direct financial support, the firm reinvests 50% of its profits into minority communities through its foundation, reinforcing Westbound’s commitment to broad, enduring impact. This approach is set to challenge traditional investment structures by prioritizing long-term equity and inclusive growth alongside profitability.

The Western Development Commission (WDC), headquartered in Ballaghaderreen, Ireland, is a state agency dedicated to promoting social and economic development in the Western Region, covering counties such as Donegal, Leitrim, Sligo, Mayo, Roscommon, Galway, and Clare. The WDC provides both equity finance and loans to businesses, community projects, and social enterprises, aiming to foster innovation and growth in these areas. In 2023, WDC reported a record year of investments, with notable funding going to companies like Peroptyx (€500,000), Xerotech (€1.5 million), and Hooke Bio (€400,000). They also invested €200,000 in Magamedia for the TV series "Obituary" filmed in Donegal​. Other portfolio companies include Achill Island Sea Salt, AeroGen, Éire Composites, and Neuravi, highlighting WDC’s focus on sectors such as renewable energy, healthcare, and innovative manufacturing. The WDC supports its investments through a combination of commercial interest loans and strategic guidance, aiming to create a significant socio-economic impact in the Western Region.

Westlake Ventures is a St. Petersburg, Florida-based investment firm founded in 2006. The firm is led and largely funded by Carl Treleaven, who serves as Principal, Chief Executive Officer, Treasurer and the registered agent on Florida corporate filings. Treleaven brings a deep operator background to investing, having spent nearly 20 years as CEO of Pharmagraphics, a multinational specialty packaging and label-printing company headquartered in Greensboro, North Carolina, and structures Westlake Ventures as a single-principal vehicle that co-invests alongside Florida angel groups, individual angel investors and selectively venture firms. Investment focus skews toward software and information technology, with additional activity in healthcare, biomedical and broader emerging-technology categories. Westlake principally backs development-stage companies based in Florida with innovative solutions to problems addressing large markets, although the portfolio also includes select non-Florida companies sourced through angel syndicates, and it generally invests as a co-investor. Across approximately 50 to 53 disclosed portfolio investments the firm has seen five acquisition exits, the most recent being teletherapy company TAO Connect, which was acquired by UpLift in March 2024. Public databases describe a wide nominal check-size range, but in practice individual ticket sizes are much smaller and reflective of seed and Series A angel-style co-investing. By pairing a seasoned operator's experience with co-investment alongside Florida angel networks, Westlake Ventures backs development-stage software, IT and healthcare founders, primarily in Florida, that target large markets with innovative solutions.

Westlake Village BioPartners is a venture capital firm based in Los Angeles, specializing in life sciences and biotechnology. Founded in 2018 by Beth Seidenberg, M.D., a former general partner at Kleiner Perkins, and Sean Harper, M.D., the firm has raised a total of $1.3 billion across three funds. Their most recent fund, launched in July 2023, raised $450 million to incubate and grow early-stage biotech companies. Westlake Village BioPartners focuses on transformative human therapeutic technologies, investing in companies from their early stages through Series B rounds. Their portfolio includes notable companies such as Latigo Biotherapeutics, which is developing non-opioid pain medicines, and Kyverna Therapeutics, which recently closed an upsized initial public offering. The firm is committed to catalyzing the Los Angeles biotech hub by supporting innovative startups and leveraging their extensive network and expertise in both scientific and business realms. Their leadership team includes experienced professionals like Mira Chaurushiya, Ph.D., and David Allison, Ph.D., who bring deep scientific and venture capital experience to the table.

What If Ventures is a venture capital firm founded in 2020 that primarily invests in mental health, addiction, and stigmatized healthcare services. Based in the United States, What If Ventures is stage-agnostic and provides flexible check sizes, focusing on early-stage investments from seed to pre-IPO. Their portfolio includes companies like TRIPP, Osmind, Alto Neuroscience, Grow Therapy, and Ellipsis Health, which are all focused on innovative solutions in the mental health space. Notable exits include Human API and several IPOs, such as ATAI Life Sciences and Field Trip Health. What If Ventures has deployed $85 million in capital across 72 portfolio companies and has over 4,100 syndicate members. The firm supports startups by addressing the gaps and stigmas in mental health care, aiming to create accessible, affordable, and effective solutions for all.

White Star Capital is a global multi-stage venture capital firm that invests in technology startups with the potential to scale internationally. With a presence in key markets like New York, London, Paris, Toronto, and Singapore, White Star has developed a reputation for backing ambitious entrepreneurs building industry-defining companies across a variety of sectors. White Star focuses on investments in Series A and B rounds, supporting startups in industries such as fintech, digital assets, e-commerce, and healthtech. Some notable portfolio companies include Tier Mobility (a leader in micro-mobility solutions), Freshly (a healthy meal delivery service acquired by Nestlé), and Butternut Box (a fast-growing pet food company). In addition, the firm has made significant strides in blockchain and Web3 technologies through its Digital Asset Fund, which targets crypto networks and blockchain-enabled businesses. The firm’s investment strategy centers around partnering closely with founders, providing not just capital but also strategic support to help startups expand across borders. White Star is deeply committed to ESG (Environmental, Social, and Governance) principles, aligning its investments with sustainability goals. They became a signatory of the UN Principles for Responsible Investment, emphasizing their focus on creating long-term, positive impact. Led by co-founders Eric Martineau-Fortin and Jean-Francois Marcoux, the firm has successfully driven numerous exits, including Dollar Shave Club and Adore Me, reflecting their expertise in scaling companies to global success.

Whitecap Venture Partners, founded in 1990 and headquartered in Toronto, is a prominent early-stage venture capital firm. They focus on investing in B2B software, healthcare technology, and food technology companies across Canada and the Northeastern United States. Notable investments include Vetster, an innovative pet wellness platform, and PartnerStack, a sales technology platform. Whitecap has made significant exits, such as the IPO of Real Matters and the acquisitions of Affinio and Classcraft. Their investment strategy centers on partnering with founders to provide the necessary capital and guidance to scale their businesses successfully. Key team members include Carey Diamond, Russell Samuels, and Shayn Diamond, who bring extensive experience and expertise to the firm. With a track record of over three decades, Whitecap Venture Partners continues to support and grow startups by leveraging their deep industry knowledge and broad network. Their recent fund, Whitecap V, closed with commitments of CAD 140 million, emphasizing their commitment to fostering innovation and supporting early-stage companies in their growth journey.

Willow Growth Partners is a Los Angeles-based early-stage venture capital firm that focuses on investing in emerging consumer brands and the technologies that support them. Founded in 2020 by Deborah Benton and Amanda Schutzbank, the firm aims to back companies that are not only innovative but also values-driven, with a strong emphasis on sustainability and transparency. The firm’s investment strategy is centered around supporting brands with strong underlying unit economics and a clear path to profitability. Willow Growth Partners typically leads the first institutional round of investment and provides extensive hands-on support, helping companies scale efficiently while maintaining their core values. Their inaugural $28 million fund, announced in 2021, reflects this approach, with a portfolio that includes companies like Bubble, Dae, and Coterie, among others. Willow Growth Partners is particularly committed to diversity, with nearly 75% of their portfolio companies led by female or minority founders. The firm’s founders bring a wealth of experience from both venture capital and operating roles, which they leverage to guide their portfolio companies through the challenges of early-stage growth.

Windham Venture Partners, founded in 2006 and headquartered in New York City, focuses on early-stage investments in the healthcare sector, particularly in medical technology, digital health, and life sciences. The firm is dedicated to investing in companies that bring significant advancements and innovations in healthcare, emphasizing transformative impact and commercialization of cutting-edge technologies. Their notable investments include companies like Alto Neuroscience, Valera Health, and SubjectWell. Windham Venture Partners has achieved successful exits with companies such as CVRx, which went public, and SubjectWell, acquired by WindRose Health Investors. The firm has made 74 investments and has seen 25 exits, showcasing a robust portfolio and strategic investment approach. Led by co-founders Roger Fine, Adam Fine, and Joseph Proto, Windham Venture Partners brings together a team of experienced professionals dedicated to supporting their portfolio companies with strategic guidance and resources. The firm collaborates with a wide range of co-investors, enhancing its ability to back high-impact ventures and drive innovation in healthcare​.

WindSail Capital Group is a Boston-based investment firm specializing in providing growth capital to companies focused on energy innovation and sustainability. Their investment strategy emphasizes flexible financing solutions that facilitate growth while minimizing dilution. WindSail typically invests in the form of secured loans, with amounts ranging from $2 million to $10 million. The firm’s notable investments include Ubees, a precision beekeeping and pollination services provider, and Axiom Cloud, which focuses on refrigerant leak detection software. Other significant portfolio companies are WeatherFlow-Tempest, which offers advanced weather stations, and Genera, a biomass supply company for the pulp and packaging industries. WindSail Capital operates predominantly within the clean energy sector, targeting industries such as energy storage, smart grid technologies, and renewable energy solutions. Their investment approach is characterized by deep industry expertise and a commitment to supporting underserved market segments. The leadership team, including Ian Bowles, Managing Director, leverages extensive experience and relationships within the energy sector to support portfolio companies effectively. This hands-on approach has enabled WindSail to maintain a robust and diverse investment portfolio, supporting companies that drive significant advancements in sustainability and energy efficiency​.

Wing Venture Capital, founded in 2013 and based in Palo Alto, California, focuses on early-stage investments in technology companies. The firm primarily invests in sectors such as AI, cybersecurity, big data, SaaS, and enterprise software. Wing is known for its deep engagement with founders, providing extensive support beyond capital to help build significant companies. Notable companies in Wing's portfolio include Snowflake, a data cloud company; Cohesity, a data management firm; and Gong, which uses AI to analyze sales calls. Other prominent investments are Pinecone, a vector database company, and Moogsoft, an AIOps platform for IT incident management. Wing's investment strategy emphasizes long-term partnerships with founders, leveraging their expertise and extensive network to support the growth of portfolio companies. They aim to be actively involved, often taking board seats and providing strategic guidance.

Winton Ventures is the venture capital arm of Winton Group, the London-headquartered quantitative investment management firm founded in 1997 by British billionaire Sir David Winton Harding and now managing approximately $13 billion in assets across systematic strategies, with offices in London, Shanghai, Abu Dhabi, New York, Hong Kong and Sydney. Winton Ventures was established in 2015 to leverage the parent group's deep in-house expertise in data science, statistical analysis and computational research as a structural advantage when investing in technology companies. The unit's thesis focuses on entrepreneurs creating breakthroughs in data-rich and data-intensive verticals, cybersecurity, energy and environment, including transformational deep-tech like fusion, data science and applied analytics, and healthcare and biotech, generally as a co-investor. Across roughly 32 disclosed investments the portfolio includes BlueVoyant in cyber defence-as-a-service, Exonar in data discovery, OxSonics in medical ultrasound therapeutics, Panaseer in continuous controls monitoring, Ripjar in open-source data intelligence, Tessian in machine-learning email security, acquired by Proofpoint in 2024, and the high-profile fusion-energy company Tokamak Energy, which raised an additional $125 million in November 2024 to commercialize transformative fusion and high-temperature superconducting-magnet technologies. Winton Ventures pairs capital with operational data-science partnership from the broader Winton organization. Specific fund size and current named partner roster for the Ventures unit are not publicly disclosed. By drawing on its parent's quantitative and data-science expertise, Winton Ventures backs founders building breakthroughs in cybersecurity, energy, analytics and healthcare, with notable exposure to frontier deep-tech such as fusion energy.

Wireframe Ventures is a venture capital firm founded in 2016, with headquarters in Mill Valley, California, and an expanded presence in New York City. The firm focuses on pre-seed and seed-stage investments, particularly in sectors that positively impact climate and health. Their mission is to back founders driven by a commitment to create innovative solutions that benefit people and the planet. Wireframe Ventures manages several funds, including the recently announced $77 million Wireframe Fund II. This fund is dedicated to supporting early-stage companies aiming to improve environmental sustainability and healthcare. The firm typically invests between $500,000 and $2 million in early-stage companies, often leading or participating in high-quality syndicates. The team at Wireframe Ventures includes co-founders Harsh Patel and Paul Straub, along with other key members such as Lily Bernicker. They bring extensive experience and a hands-on approach to support their portfolio companies from the initial investment through to product-market fit and subsequent funding rounds. Notable investments by Wireframe Ventures include Mammoth Biosciences, SPAN.io, MycoWorks, Electriphi, and Enveda Biosciences. These companies exemplify Wireframe's focus on innovative technologies that address critical issues in health and sustainability. The firm has a strong track record, with over 70% of their portfolio companies raising institutional Series A funding within 15 months of Wireframe's initial investment.

Wisdom Ventures is a unique venture capital firm founded with a mission to promote mindfulness, well-being, and human connection through its investments. The firm recently closed its first fund, raising $10 million in an oversubscribed round. The fund supports early-stage companies across sectors like mental health, AI, and workplace well-being, with notable investments in startups such as Betterleave, Alkeme, and Seven Starling. Wisdom Ventures is dedicated to nurturing a new paradigm where technology and business serve humanity rather than profit from division and addiction. Led by a team of seasoned professionals, including long-time Google executive Bradley Horowitz, meditation teacher Jack Kornfield, and well-being expert Ruchika Sikri, the firm blends capital with a commitment to personal growth and conscious leadership. The fund has attracted investors such as Reid Hoffman and Evan Williams, aligning with its vision of fostering a compassionate and mindful entrepreneurial ecosystem. Wisdom Ventures places a strong emphasis on diversity, with 50% of its Limited Partners and 80% of its founders representing diverse backgrounds. As the firm looks ahead, it plans to continue supporting aligned founders while preparing for a larger Fund II.

Woodstock Fund is a global venture capital firm with a sharp focus on blockchain technology, decentralized finance (DeFi), and Web 3.0 ecosystems. Founded in 2019, the firm has quickly built a strong portfolio across early and growth-stage companies in sectors such as decentralized protocols, NFTs, and tokenization. Notable investments include Router Protocol, a cross-chain liquidity platform, Transak, a crypto on-ramp provider, and Covalent, a blockchain data querying service. The fund is headquartered in the Cayman Islands with offices in India and the UAE, bridging investment opportunities between Asia, the Middle East, and global markets. Woodstock's investment strategy is highly research-driven, with a focus on emerging technologies that push the boundaries of Web 3.0. They target startups in Series A and pre-seed stages, with check sizes ranging from $1M to $5M. The firm is also active in infrastructure and protocol development, helping to shape governance and ecosystem growth for the projects they back. Woodstock’s investment horizon is long-term, often employing a five-year lockup period for their investors. Led by co-founders Pranav Sharma and Himanshu Yadav, Woodstock Fund has gained a reputation for its deep expertise in decentralized technologies and its hands-on approach to supporting portfolio companies. This commitment is reflected in its strategic role in building infrastructure around blockchain and guiding early-stage startups through the complex landscape of decentralized ecosystems.

World Fund is a leading European climate tech venture capital firm that focuses on backing startups with the potential to significantly reduce global carbon emissions. Founded in 2021 by Daria Saharova, Danijel Višević, Tim Schumacher, and Craig Douglas, the fund aims to support companies that can save at least 100 megatonnes of CO2 equivalent per year. With a mission to save 2 gigatons of emissions by 2040, World Fund invests in early to growth-stage startups across various sectors, including energy, food, agriculture, manufacturing, and mobility. Based in Berlin, Munich, Cologne, and Amsterdam, World Fund has raised the largest first-time fund in European climate VC history, securing €300 million to invest in groundbreaking climate technologies. The firm leverages a rigorous methodology to assess the Climate Performance Potential (CPP) of startups, ensuring that each investment aligns with their vision of creating a regenerative world. Notable investments include companies like IQM Quantum Computers, Space Forge, and Planet A Foods. The fund is supported by a diverse team of entrepreneurs, scientists, and engineers, along with a network of around 60 limited partners, including notable figures from the European tech ecosystem. This combination of deep industry expertise and a strong commitment to climate impact positions World Fund as a pivotal player in the fight against climate change in Europe.

WorldQuant Ventures is an early-stage venture capital firm founded in 2014 by Igor Tulchinsky. The firm primarily focuses on disruptive technologies in data, finance, healthcare IT, AI/ML, quantum computing, and space. Based in Old Greenwich, Connecticut, WorldQuant Ventures supports its portfolio companies through strategic advice and introductions, leveraging its extensive experience in technology and data science​. Notable investments include companies like Dataminr, Pico, Credijusto, Benzinga, IonQ, PsiQuantum, Genies, and Skyroot. The firm typically invests at the pre-seed, seed, and Series A stages, with an emphasis on being long-term partners to their portfolio companies​. WorldQuant Ventures is managed by Steve Lau, who brings significant expertise from his background in financial technology and trading. The firm also benefits from the strategic vision of its founder, Igor Tulchinsky, who has a rich history in quantitative trading and venture capital​.

Worth Capital is a UK-based venture capital firm that specializes in early-stage investments, focusing on startups with innovative, market-disrupting products or services. They typically invest up to £400,000 in businesses that qualify for the Seed Enterprise Investment Scheme (SEIS) or Enterprise Investment Scheme (EIS). Their investment approach centers around identifying brands that have strong potential for growth and customer loyalty, particularly those operating in fragmented or underserved markets. Worth Capital’s portfolio is diverse, covering both B2B and consumer sectors. Notable investments include Fox Robotics, an agricultural technology company, and Kanda, a fintech solution for tradespeople. The firm values market insight and problem-solving over mere technological hype, emphasizing the importance of founders who understand their markets deeply. Geographically, Worth Capital is committed to supporting UK-based startups, with a significant portion of their investments going to businesses outside of London. Their founders, Matthew Cushen and Paul Soanes, bring decades of entrepreneurial and investment experience, providing not only capital but strategic guidance to help their portfolio companies scale successfully. For startups looking to engage, Worth Capital values clear market strategies and innovation, with a preference for businesses aiming to build enduring, loved brands​.

WuXi Healthcare Ventures was founded in 2011 as the corporate venture arm of WuXi PharmaTech, now WuXi AppTec, the China-based contract research and manufacturing giant. The firm was headquartered in Cambridge, Massachusetts with a second office in Shanghai, China, and ran an explicit cross-border 'find in U.S. and build in China' strategy, identifying promising life sciences companies in the US and supporting their development with access to the China market and WuXi's R&D platform, generally as a co-investor. WuXi Healthcare Ventures II, L.P. closed in December 2015 at $290 million, exceeding its $250M target. Founding leadership included Dr. Ge Li, founder of WuXi PharmaTech, and Edward Hu, CFO/CIO of WuXi AppTec, as non-operating partners, and operating partners including Managing Partner Wei Li. The portfolio spanned both US biotechs and emerging Chinese drug developers, including Twist Bioscience, Unity Biotechnology, Ideaya Bioscience, Syros Pharmaceuticals, CStone Pharmaceuticals, Hua Medicine, Antengene Corporation, Refuge Biotechnologies, XW Laboratories, LifeMine Therapeutics, Vivace Therapeutics and Forerunner Medical. The firm exited several landmark companies including Agios Pharmaceuticals in cancer metabolism, Foundation Medicine, later acquired by Roche, and Juno Therapeutics, later acquired by Celgene. On May 18, 2017, WuXi Healthcare Ventures merged with Frontline BioVentures to form 6 Dimensions Capital, an approximately $800M AUM biotech-focused VC chaired by Ge Li with Frontline founder Dr. Leon Chen as CEO. New investment activity is now conducted under the 6 Dimensions Capital brand. With its cross-border model, WuXi Healthcare Ventures bridged US life-sciences innovation and the China market.

WVV Capital is a $100 million venture capital firm based in Milwaukee, Wisconsin, founded in 2018. The firm is a joint partnership between major corporations like Advocate Aurora Health, Foxconn, Johnson Controls, and Northwestern Mutual. WVV Capital focuses on investing in early-stage startups across healthcare, manufacturing, financial services, and building technologies, often targeting ventures that harness artificial intelligence and advanced data solutions. WVV Capital offers more than just funding—its unique approach involves building strategic relationships between startups and large corporations, facilitating growth through data partnerships and corporate support. Their portfolio includes companies like Caspar AI and Paxton AI, which focus on healthcare and productivity technologies, respectively. The firm has a diverse and experienced team, led by professionals like Jason Franklin, Ph.D., and Danielle D’Agostaro, both with extensive backgrounds in venture capital and startup operations. With a strong emphasis on AI-driven innovation, WVV Capital aims to bridge the gap between cutting-edge startups and data-rich corporations, helping companies scale effectively in competitive industries. Their broad network of corporate partners and seasoned operators allows them to support startups from initial investment through to large-scale growth.

Xenia Venture Capital is an Israeli high-tech and life sciences investment company founded in 2003 and publicly traded on the Tel Aviv Stock Exchange. Headquartered in Tel Aviv, Xenia invests in early-stage Israeli companies across high-tech and medical technology, with an increasing focus on life sciences. A core element of its platform is a 50% stake in VLX, a technological incubator operating under the Israel Innovation Authority's incubator program that supports data-driven biotech, pharma and digital-pharma startups. Beyond capital, Xenia provides portfolio companies with mentoring, business and strategic counseling, fundraising assistance, exit planning, and shared back-office infrastructure, finance, accounting, logistics and office support, services well suited to first-time scientific founders coming out of academia or the Israeli Innovation Authority incubator pipeline, and it generally invests as a co-investor. Since inception the firm has invested in more than 40 companies and notched one IPO and at least six acquisitions; flagship outcomes include the June 2020 NASDAQ IPO of PolyPid at roughly a $273M market cap, the acquisition of orthopedic device company OrthoSpace by Stryker, and the 2021 exit of MEC software vendor Saguna. Recent activity remains steady, with its most recent reported investment on April 8, 2025 in Arcuro Medical in surgical devices. The firm's leadership has included CEO Lars Thoren and previously Eli Sorzon, and the team comprises roughly eight people including seven partners. By pairing capital with incubation and back-office support, Xenia Venture Capital backs early-stage Israeli high-tech and life-sciences founders.

Xfund is an early-stage venture capital firm that supports lateral thinkers and entrepreneurs who experiment across disciplines. Established in 2014 through a unique partnership with leading venture capital firms and top research universities, Xfund is co-managed by Patrick Chung and Brandon Farwell. The firm focuses on backing founders with multidisciplinary skills and a strong commitment to innovation and execution. Xfund aims to invest in individuals who are not only technically proficient but also possess a deep understanding of their field's broader implications. Their investment approach is designed to provide significant value through a combination of venture capital expertise, university partnerships, and industry connections. This structure allows Xfund to offer unparalleled support to its portfolio companies. The firm has raised several funds, including the latest, Xfund 3, which closed at $120 million. This fund continues Xfund's mission of fostering university-based innovation and supporting startups across various stages of growth. Xfund's notable investments include companies like Philo, Kensho, and 23andMe, reflecting their commitment to high-impact ventures. Xfund operates out of Cambridge, Massachusetts, and Palo Alto, California, reinforcing its connection to leading academic and innovation hubs. For more information, you can visit their official website at xfund.com.

XYZ Venture Capital, founded by Ross Fubini in 2017, focuses on early-stage investments in fintech, enterprise, and what they call "tech-forgotten" sectors like insurance and public services. Their notable portfolio includes companies such as Anduril, Mosaic, and Saltbox, many of which have ties to Fubini's strong network, especially with Palantir alumni. The firm’s strategy emphasizes rapid execution, helping founders accelerate their business from idea to Series A with hands-on support in areas like go-to-market strategy, fundraising, and product development. XYZ targets investments primarily in the U.S., with a presence on both coasts, and prefers to back founders who are solving hard societal problems, especially leveraging technologies like AI. The average check size isn’t disclosed, but the firm has raised several significant funds, including an $80M Fund II, to fuel early-stage growth. XYZ often leads rounds and positions itself as a deeply engaged partner, offering more than just capital. They look for founders who are curious, adaptable, and committed to execution, and prioritize building close, long-term relationships. The team includes key partners like Chauncey Hamilton and Art Clarke, both of whom bring extensive venture and operational experience. Together, they help XYZ become an indispensable partner to founders, offering deep industry expertise and critical connections to propel startups forward..

Y Combinator, a premier startup accelerator, has backed some of the world's most successful companies, including Airbnb, Dropbox, and Stripe. The fund's portfolio is impressive, boasting over 5,000 startups with more than 290 private companies valued over $150 million and over 90 valued at more than $1 billion​. Y Combinator's investment focus spans several industries, primarily B2B software and services (43%), financial technology (19%), consumer (13%), and healthcare (12%)​​. Geographically, YC is centered in Silicon Valley, with 59% of its companies headquartered in the Bay Area, but it also supports startups globally, including in countries like India, the UK, and Nigeria​​. YC's strategy involves investing $150,000 in a large number of startups twice a year, providing them with three months of intensive mentorship, networking, and resources. They prefer to invest in early-stage startups and often continue to support companies through follow-on funding rounds​. The typical check size is $150,000, and YC often leads the initial seed rounds. Recently, they've been very active, continuously adding new companies to their portfolio and expanding their global reach​​. Approaching YC involves applying for their biannual batches, with a focus on showing strong product-market fit and growth potential. The team is led by notable figures such as Michael Seibel, the CEO, who brings a wealth of experience in startup growth and acceleration. YC's network of alumni and mentors is a key asset, providing ongoing support and advice to new startups​.

Yes VC, founded in 2018 by Caterina Fake and Jyri Engeström, is a venture capital firm based in San Francisco that focuses on investing in pre-seed and seed-stage startups. The firm is known for backing category-defining companies across a diverse range of industries, including artificial intelligence, climate tech, consumer brands, and digital infrastructure. Notable investments from Yes VC's portfolio include Adept AI, Boom Supersonic, and Lovevery. Adept AI is working on developing general intelligence by enabling humans and computers to collaborate creatively, while Boom Supersonic is building a non-fossil-powered supersonic passenger plane. Lovevery creates award-winning, Montessori-inspired toys and subscription boxes for babies and toddlers. Yes VC is also actively investing in climate tech, with companies like Running Tide, which focuses on carbon sequestration by growing biomass and sinking it in the deep ocean, and Steady Energy, which is developing zero-emission heating plants powered by advanced nuclear reactors. Additionally, the firm supports innovative digital infrastructure solutions, such as OneSignal, a customer engagement platform, and Reconnect, which improves outcomes for individuals in the criminal justice system. The firm's commitment to diversity is evident, with a significant portion of its investments going into companies founded by women or people of color. This approach aligns with their mission to support transformative technologies and innovative business models that have the potential to make a substantial impact.

The Yield Lab is a venture capital firm dedicated to transforming the agri-food sector by investing in early-stage companies across North America, Europe, Latin America, and Asia Pacific. Their portfolio includes notable startups such as Pluton Biosciences, which specializes in biotech innovations, and GroGuru, which focuses on strategic irrigation management for farmers. With a geographic focus that spans multiple continents, The Yield Lab invests in high-impact companies with technologies in areas like digital agriculture, crop health, and sustainable farming practices. Their investment strategy typically involves funding from $100,000 to $1.5 million for early-stage ventures, providing not just capital but also access to a global network of experts and industry partners to help scale and commercialize these innovations internationally. The Yield Lab has a keen focus on sustainability and aims to support companies that can revolutionize food systems and contribute to environmental conservation. For instance, their investment in RootWave, a company using electricides for sustainable weed control, reflects their commitment to eco-friendly solutions. Key team members include Pat Pinkston and Sherri Brown in North America, and Paul Finnerty and Brian Clevinger in Europe, all of whom bring extensive experience in venture capital and agri-food industries. They maintain a collaborative approach, leveraging their combined expertise to drive growth and innovation within their portfolio companies.

Ymer Venture Capital Asia is a Hong Kong-based venture capital firm that partnered with early-stage Asian startups across technology, life sciences and renewable energy. The firm describes its mandate as backing high-growth Asian businesses with the potential to lead market disruption, preferring to build around outstanding founders or teams with powerful technology and market vision, and providing capital alongside strategic and operational support, generally as a co-investor. The portfolio is small and concentrated, with five publicly tracked investments: language-learning platform ChinesePod, social-commerce app Kwestr, and several others across application software, leisure facilities and educational software. Public sources show no investment activity since November 2010, the last reported deal being Kwestr, and aggregator databases do not disclose current fund size, partner roster or AUM. There is some inconsistency between sources: one summary lists the firm as founded in 2018, while the deal-history record extends only through 2010, suggesting either an earlier founding date with a long dormant period or a possible relaunch. The firm operates under the website ymerfund.com, but the site has been largely inaccessible to modern crawlers. Ymer Venture Capital Asia should be treated as a small and likely inactive Hong Kong VC with a historic portfolio rather than a currently deploying fund. During its active period it backed early-stage Asian founders in technology, life sciences and renewable energy, building a concentrated portfolio anchored by names such as ChinesePod and Kwestr while providing strategic and operational support alongside capital.

Yonjin Venture LLC is a life sciences-focused venture capital firm established in 2018 and headquartered in Cambridge, Massachusetts. The firm operates as the North America and Europe investment arm of Shanghai-based Yongjin Group, founded in 1995, which positions itself as a diversified capital-markets financial-services institution. Yonjin's sister vehicle is China-based Yonghua Capital, and the two share parent-level resources and deal flow. Yonjin Venture's mandate is early- to mid-stage life sciences, specifically therapeutic drug discovery, diagnostics and medical devices, and it routinely participates as a syndicate co-investor alongside leading US biotech specialists rather than as a lead investor. The team is reported at roughly 10 people including 7 partners. Public portfolio companies include Rapafusyn Pharmaceuticals in drug discovery, its most recent investment in September 2025, CSA Medical, a Series D-II in September 2024, HistoSonics, a focused-ultrasound therapeutic platform, TECLens in ophthalmology devices, Libra Therapeutics in neurodegeneration, a Series A co-led with Boehringer Ingelheim Venture Fund, and OncoResponse in cancer-immunotherapy antibodies, co-invested alongside MD Anderson, ARCH Venture Partners, Canaan Partners, Redmile and GreatPoint. To date the firm has roughly 17 reported investments and one IPO exit, C4 Therapeutics, which went public in October 2020. Fund size and AUM are not publicly disclosed. As the North America and Europe arm of a Chinese financial-services group, Yonjin Ventures co-invests alongside leading US biotech specialists in early- to mid-stage therapeutics, diagnostics and medical devices.

Zeno Ventures, founded in 2016 by Christopher Kile and Duarte Moreira, focuses on early to growth-stage investments in high-potential technology companies. Based in San Francisco, Zeno Ventures primarily invests in consumer and enterprise markets, including transportation, logistics, fintech, and 3D printing sectors. Their notable investments include AvantStay, a hospitality tech startup; Mighty Buildings, a construction tech company; and Mercury, a fintech platform​. Zeno Ventures typically invests around $7 million per round and averages about three transactions per year. While they occasionally lead investment rounds, they often co-invest with other prominent firms like Khosla Ventures and Bold Capital Partners. The firm is known for its collaborative approach, sharing opportunities and working closely with other investors to support portfolio companies throughout their growth. The key team members, Christopher Kile and Duarte Moreira, bring extensive experience in venture capital and entrepreneurship. They focus on building strong relationships with founders and providing strategic support to scale their businesses. Zeno Ventures' geographic focus spans primarily the United States, with a significant presence in tech hubs like San Francisco and Los Angeles. For startups looking to partner with Zeno Ventures, it's essential to demonstrate exceptional management and high growth potential in their pitch. Approaching the firm through warm introductions and showcasing alignment with their investment thesis increases the likelihood of securing an investment.

Zero Carbon Capital (ZCC) is a venture capital firm based in Hampshire, UK, specializing in pre-seed and seed-stage investments in companies that develop hard-science solutions to address the global challenge of decarbonization. Founded in 2019 by Pippa and Alex Gawley, ZCC is dedicated to supporting startups across Europe that have the potential to significantly reduce carbon emissions through innovative technologies. ZCC's investment strategy is deeply rooted in scientific rigor and environmental stewardship, focusing on startups that can make substantial impacts in areas with significant emission challenges. Their portfolio includes companies like Level Nine, which pioneers chemical manufacturing from biological feedstocks, Ionate, which develops smart transformers for renewable energy grids, and RepAir, which innovates low-power electrochemical direct air capture technologies. The firm recently closed a £20 million fund, backed by a diverse group of investors, including Isomer Capital and Green Future Investments. This fund is aimed at accelerating early-stage climate tech ventures that can contribute meaningfully to global carbon reduction. ZCC's team is composed of highly experienced professionals with strong scientific and technological backgrounds, such as Pippa Gawley, who brings years of climate tech investing experience from both the US and Europe, and Sarah Jones, PhD, who has a background in Bioprocess Engineering and Environmental Biotechnology. ZCC is not only an investor but also a strategic partner, providing its portfolio companies with the resources and guidance needed to scale their innovations effectively and make a lasting impact on the planet.

Zetta Venture Partners is a San Francisco-based venture capital firm founded in 2013 by Mark Gorenberg. The firm focuses exclusively on early-stage investments in AI-driven B2B companies. Zetta's portfolio includes prominent startups such as Clearbit, Lilt, and Opsani, which highlight their commitment to the intelligent software sector. Zetta Venture Partners targets companies in North America and Europe, providing initial investments ranging from seed to Series B stages. The firm's strategy emphasizes hands-on support for founders, particularly in scaling AI models into market-leading products and infrastructures. They position themselves as crucial partners to impactful AI and infrastructure startups, offering expertise in areas like business development, strategic partnerships, and scaling operations. The team includes experienced professionals like Managing Directors Jocelyn Goldfein and Apoorva Pandhi, based in San Francisco, and Partner Dylan Reid in New York. They have a robust network of operators and advisors, ensuring startups receive comprehensive support throughout their growth journey. Zetta's investments are deeply rooted in AI applications and infrastructure, reinforcing their belief in the transformative potential of AI across various industries. This focus has allowed them to build a portfolio that not only aims for financial returns but also contributes significantly to technological advancements. By leveraging their extensive industry connections and deep technical expertise, Zetta Venture Partners helps AI-driven startups navigate the complexities of market entry and growth, making them a formidable player in the venture capital landscape​.

Zhangjiang Torch Venture Capital Co is an early- and growth-stage venture capital firm founded in November 2008 as the dedicated investment arm of Zhangjiang High Tech Park Group, the operating entity behind Shanghai's flagship Zhangjiang Hi-Tech Park in Pudong, a national-level science park known as 'China's Medicine Valley' for its dense concentration of biotech, pharmaceutical, semiconductor and advanced-manufacturing companies. The fund concentrates on the strategic sectors that Zhangjiang Hi-Tech Park is built to nurture: integrated circuits and application-specific semiconductors, next-generation information technology, biomedicine and high-performance medical devices, intelligent manufacturing, and new-energy and advanced-materials technologies, generally as a co-investor. Typical deal sizes have been reported in the $5M to $10M range, and across the fund's life it has made approximately 64 disclosed investments. Notable portfolio companies include Yanwei Semiconductor, its most recent reported investment in July 2023, Shengfang Technology, Xinyu New Material, Aqbiopharma and SeeYA Technology, its latest reported portfolio exit in March 2026. Public databases describe the entity as permanently closed at the original Zhangjiang Torch level, with the broader Zhangjiang state-affiliated venture activity continuing under related vehicles such as Zhangjiang Hi-Tech Investment, Zhangjiang Haocheng and ZJ Innopark, which remained active through 2025 to 2026. Fund leadership ties back to the Zhangjiang High Tech Park Group rather than named external GPs. As the investment arm of one of China's leading science parks, Zhangjiang Torch Venture Capital backed semiconductor, biomedicine, intelligent-manufacturing and advanced-materials companies aligned with the park's strategic sectors.

ZORA Ventures is a Tel Aviv-based impact venture capital firm founded in 2017 by Vanessa Bartram. Since inception it has been a leader in Israel's impact space as an early-stage deep tech investor, backing leading scientists and entrepreneurs with globally scalable technology to combat climate change and cultivate sustainable food systems. The firm positions itself as a hands-on investor and operator working intimately with its teams to convert lab-scale innovations into mainstream food, agriculture and climate solutions for the world's largest corporations. Its first vehicle, the ZORA Israel Impact Fund, is an oversubscribed US$10M fund invested in Israel's leading foodtech, agtech and climate-tech startups; each portfolio company targets significant, quantifiable progress toward a UN Sustainable Development Goal, climate change, environment, health access or food security, while aiming to deliver top-quartile venture returns. ZORA invests primarily at seed and Series A in Israel-based startups, with a portfolio of roughly 12 companies spanning Israel, the US and the UK, generally as a co-investor. Notable investments include WeedOUT in bio-based agtech, Wasteless in food-waste software, Solutum in plastic-alternative packaging, Amai Proteins in designer proteins and healthy sweeteners, and Forsea Foods in cultivated seafood, with at least one exit, CodeMonkey. The firm has partnered with Rho Impact to advance climate innovation and impact measurement. Founder and Managing Partner Vanessa Bartram is an impact entrepreneur turned investor, previously founder of the Miami-based HR company WorkSquare; she holds an MBA from Harvard and a BA from Princeton. ZORA backs Israeli foodtech, agtech and climate founders.

Zukunftsfonds Heilbronn, now rebranded as D11Z Ventures, is a prominent venture capital firm based in Heilbronn, Germany. The firm focuses on early-stage investments, particularly in digital business models across sectors like AI/Deep Tech, B2B SaaS, and asset-light IoT. D11Z Ventures, formerly known as Zukunftsfonds Heilbronn, has a clear mission to promote and support innovative digital ventures with both national and international impact, aiming to be the leading pre-seed and seed VC fund for AI in Europe. D11Z Ventures is known for its hands-on approach, providing startups not just with capital but also with strategic guidance, industry expertise, and access to a broad network of partners. The firm’s portfolio is diverse, with investments in startups that are shaping the future of various industries through technological innovation. Their rebranding to D11Z Ventures reflects a renewed commitment to innovation and sustainability in the rapidly evolving tech landscape. The firm is led by a team of experienced professionals who are deeply involved in the German and European startup ecosystems, actively supporting companies from the very early stages through to their growth and scaling phases​.